Daptomycin as Adjunctive Therapy for Staphylococcus Aureus Bacteremia

PHASE4CompletedINTERVENTIONAL

Enrollment

102

Participants

Timeline

Start Date

December 1, 2016

Primary Completion Date

July 31, 2019

Study Completion Date

September 30, 2019

Conditions

Methicillin Susceptible Staphylococcus Aureus SepticemiaBacteremia

Interventions

DRUG

Daptomycin

Adjuvant therapy for up to five days

OTHER

Placebo

Trial Locations (1)

McGill University Health Centre (Royal Victoria Hospital, Montreal Neurological Hospital, and Montreal General Hospital), Montreal

All Listed Sponsors

lead

McGill University Health Centre/Research Institute of the McGill University Health Centre

OTHER

NCT02972983 - Daptomycin as Adjunctive Therapy for Staphylococcus Aureus Bacteremia | Biotech Hunter | Biotech Hunter